Научно-практический журнал
«Клиническая физиология кровообращения»

ISSN 1814-6910 (Print)
ISSN 2410-9134 (Online)

 

Главный редактор

Лео Антонович Бокерия, доктор медицинских наук, профессор, академик РАН и РАМН, президент ФГБУ «НМИЦ ССХ им. А.Н. Бакулева» МЗ РФ


Каталог статей ➤ Клиническая физиология кровообращения. 2016; 13 (2): 52-121 ➤ Этиология и патогенез острой печеночной недостаточности

Этиология и патогенез острой печеночной недостаточности

Авторы: Ярустовский М.Б., Абрамян М.В., Комардина Е.В.

Организация:
ФГБУ «Научный центр сердечно-сосудистой хирургии им. А.Н. Бакулева» (директор — академик РАН и РАМН Л.А. Бокерия) Минздрава России, Рублевское шоссе, 135, Москва, 121552, Российская Федерация

Для корреспонденции: Сведения доступны для зарегистрированных пользователей.

Раздел: Обзоры

УДК: 616.36-002.4-008.64

Библиографическая ссылка: Клиническая физиология кровообращения. 2016; 13 (2): 75-84

Цитировать как: Ярустовский М.Б., Абрамян М.В., Комардина Е.В.. Этиология и патогенез острой печеночной недостаточности. Клиническая физиология кровообращения. 2016; 13 (2): 75-84. DOI:

Ключевые слова: острая печеночная недостаточность, этиология, печеночная энцефалопатия, гепа­торенальный синдром, сепсис, ишемический гепатит

Поступила / Принята к печати:  26.05.2016/29.05.2016

Скачать (Download)


Аннотация

Острая печеночная недостаточность нередко является компонентом синдрома полиорганной дис­функции, что значительно повышает уровень летальности. В данном обзоре представлены современ­ные данные по этиологии и патогенезу острой печеночной недостаточности: рассмотрены синдром эндогенной интоксикации, печеночная энцефалопатия, синдром системного воспалительного отве­та, гепаторенальный синдром, а также изменения системы гемостаза. Изложена концепция патоге­неза острой печеночной недостаточности при сепсисе и ишемическом гепатите. Понимание меха­низмов, лежащих в основе острой печеночной недостаточности, позволяет оптимизировать терапевтические стратегии

Литература

1. O'Grady J.G. Acute liver failure. J. Postgrad. Med. 2005; 81: 148-54.

2. Larson A.M. Diagnosis and management of acute liver failure. Cun: Opin. Gastroenterol. 2010; 26: 214—21.

3. Bernal W, Auzinger G., Dhawan A., Wendon J. Acute liver failure. Lancet. 2010; 376: 190—201.

4. Lee W.M. Etiologies of acute liver failure. Semin. Liver. Dis. 2008; 28: 142-52.

5. Mauss S., Berg T., Rockston J., Sarrazin C., Wedemeyer H. Hepatology: A clinical textbook. 6th edition. Flying Publisher; 2015.


6. Hadem J., Tacke F., Bruns T Etiologies and outcomes of acute liver failure in Germany. Clin. Gastroenterol. Hepatol. 2012; 10: 664-9.

7. Hussaini S.H., Farrington E.A. Idiosyncratic drug- induced liver injury: an overview. Expert Opin. Drug. Saf. 2007; 6 (6): 673-84.

8. Metushi I.G., Sanders C. Acute Liver Study Group. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver fail­ure. Hepatology. 2014; 59 (3): 1084—93.

9. Amathieu R., Levesque E., Merle J.C. et al. Severe toxic acute liver failure: etiology and treatment. Ann. Fr. Anesth. Reanim. 2013; 32 (6): 416—21.

10. Pischke S., Behrendt R, Bock C.T et al. Hepatitis E in Germany — an under-reported infectious disease. Detsch ArzteblInt. 2014; ill (35-36): 577-83.

11. Manka R, Bechmann L.P, Coombes J.D. et al. Hepatitis E Virus Infection as a Possible Cause of Acute Liver Failure in Europe. Clin. Gastroenterol. Hepatol. 2015; 13 (10): 1836-42.

12. Crossan C.L., Simpson K.J., Craig D.G. et al. Hepatitis E virus in patients with acute severe liver injury. World J. Hepatol. 2014; 6 (6): 426-34.

13. Kathemann S., Bechmann L.P, Sowa J.P. et al. Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center. Ann. Hepatol. 2015; 14 (5): 722-8.

14. Schwarz K.B., Dell Olio D., Lobritto S.J. et al. Pediatric Acute Liver Failure Study Group. Analysis of viral testing in nonacetaminophen pediatric acute liver failure. J. Pediatr. Gastroenterol. Nutr. 2014; 59 (5): 616-23.

15. Hegarty R., Hadzic N., Gissen P, Dhawan A. Inherited metabolic disorders presenting as acute liver failure in newborns and young children: King's College Hospital experience. Eur. J. Pediatr. 2015; 174 (10): 1387—92.

16. Sundaram S.S., Alonso E.M., Narkewicz M.R. et al. Pediatric Acute Liver Failure Study Group. Characterization and outcomes of young infants with acute liver failure. J. Pediatr. 2011; 159 (5): 813—8.

17. Ramah J.S., Kazuhiro K., Morimatsu H. et al. Severe ischemic early liver injury after cardiac surgery. Ann. Thorac. Surg. 2002; 74: 1601—6.

18. Coralli R.J., Crawley I.S. Hepatic pulsations in con­strictive pericarditis. Am. J. Cardiol 1986; 58: 370.

19. Bernal W, Hyyrylainen A., Gera A., AudimoolamV.K., McPhail M.J., Auzinger G. et al. Lessons from look­back in acute liver failure? A single centre experience of 3300 patients. J. Hepatol. 2013; 59 (1): 74—80.

20. Jaeschke H., Lie J. Neutrophil depletion protects against murine acetaminophen hepatotoxicity: another perspective. Hepatology. 2007; 45: 1588—9.

21. Basile A.S., Harrison P.M., Hughes R.D. et al. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology. 1994; 19: 112—21.

22. Schafer D.F., Jones E.A. Hepatic encephalopathy and the gamma-amino-butyric acid neurotransmitter sys­tem. Lancet. 1982; 11: 18—20.

23. Pemey R, Butterworth R.F., Mousseau D.D. et al. Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of enca- phalopathy and pharmaceutical benzodiazepine intake. Metab. Brain. Dis. 1998; 13: 201—10.

24. Oettl K., Bimer-Gruenberger R., Spindelboeck W et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J. Hepatol. 2013; 59 (5): 978—83.

25. Clemmesen O. Splanchnic circulation and metabolism in patients with acute liver failure. Dan. Med. Bull. 2002; 49 (3): 177-93.

26. Etogo-Asse F.E., Vincent R.P., Hughes S.A. High den­sity lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness. Liver Int. 2012; 32: 128-36.

27. Manka R, Olliges V., Bechmann L.P. et al. Low levels of blood lipids are associated with etiology and letal out­come in acute liver failure. PLoS. One. 2014; 9 (7).

28. Aronson L., Gacad R.C., Kaminsky-Russ K. Eviden­ce gut production of endogenous benzodiazepines: implications for hepatic encephalopathy. Gastro­enterology. 1996; 110: 1144.

29. O'Grady J.G., Schalm S.W., Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993; 342: 273-5.

30. Jayakumar A.R., Rama Rao K.V., Norenberg M.D. Neuroinflammation in hepatic encephalopathy: mech­anistic aspects. I. Clin. Exp. Hepatol. 2015; 5 (Suppl. 1): S21-8.

31. Chastre A., Belanger M., Beauchesne E. et al. Inflam­matory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute Uver failure and its neurological complications. PLoS One. 2012; 7 (11).

32. Jiang W., Desjardins R, Butterworth R.F. Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocy­cline. I. Neurochem. 2009; 109 (2): 485—93.

33. Bemeur C., Butterworth R.F. Liver-brain proinflamma­tory signalling in acute liver failure: role in the patho­genesis of hepatic encephalopathy and brain edema. Metab. Brain. Dis. 2013; 28 (2): 145—50.

34. Butterworth R.F. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat. Rev. Gastroenterol. Hepatol. 2013; 10 (9): 522—8.

35. Shawcross D.L., Wendon J.A. The neurological mani­festations of acute liver failure. Neurochem. Int. 2012; 60 (7): 662-71.

36. Taylor N.J., Nishtala A., Manakkat Vijay G.K. et al. Circulating neutrophil dysfunction in acute liver failure. Hepatology. 2013; 57 (3): 1142-52.

37. Rule J.A., Hynan L.S., Attar N. et al. Acute Liver Failure Study Group. Procalcitonin identifies cell injury, not bacterial infection, in acute liver failure. PLoS One. 2015; 10(9).

38. Mahmoud Abu-Amara, Shi Yu Yang, Alexander Seifalian et al. The nitric oxide pathway — evidence and mechanisms for protection against liver ischaemia reperfusion injury. Liver Int. 2012; 32 (4): 531—43.

39. Urrunaga N.H., Magder L.S., Weir M.R. et al. Prevalence, Severity, and Impact of Renal Dysfunction in Acute Liver Failure on the US Liver Transplant Waiting List. Dig. Dis. Sci. 2016; 61 (1): 309-16.

40. Pillebout E. Diagnosis and therapy of the hepatorenal syndrome. Dtsch. Med. Wochenschr. 2015; 140 (14): 1083-90.

41. Saracyn M., Z^bkowski T, Zdanowski R. et al. Effect of nitric oxide pathway regulation on water/sodium bal­ance and renal function in a rodent model of acute liver and renal failure. Med. Sci. Monit. 2014; 20: 1735—44.

42. Romano T.G., Vieira J.M. Jr. Do Biliary Salts Have Role on Acute Kidney Injury Development? I. Clin. Med. Res. 2015; 7 (9): 667-71.

43. Zager R.A., Johnson A.C., Frostad KB. Acute hepatic ischemic-reperfusion injury induces a renal cortical "stress response", renal "cytoresistance", and an endo­toxin hyperresponsive state. Am. J. Physiol. Renal. Physiol. 2014; 307 (7): 856-68.

44. Angeli P, Morando E, Cavallin M., Piano S. Hepatorenal syndrome. Contrib. Nephrol. 2011; 174: 46-55.

45. Lisman T, Caldwell S.H., Burroughs A.K. et al. Coagulation in Liver Disease Study Group. Hemostasis and thrombosis in patients with liver disease: the ups and downs. I. Hepatol. 2010; 53 (2): 362—71.

46. Northup P.G., Caldwell S.H. Coagulation in liver dis­ease: a guide for the clinician. Clin. Gastroenterol. Hepatol. 2013; 11 (9): 1064-74.

47. Lisman T, Stravitz R.T Rebalanced Hemostasis in Patients with Acute Liver Failure. Semin. Thromb. Hemost. 2015; 41 (5): 468-73.


48. Hugenholtz G.C., Adelmeijer J., Meijers J.C. et al. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology. 2013; 58 (2): 752-61.

49. Audimoolam V.K., McPhail M.J., Wendon J.A. et al. Lung injury and its prognostic significance in acute liver failure. Grit. Care Med. 2014; 42 (3): 592-600.

50. Patel J.J., Taneja A., Niccum D. et al. The asso­ciation of serum bilirubin levels on the outcomes of severe sepsis. I. Intensive Care Med. 2015; 30 (1): 23-9.

51. Nesseler N., Launey Y, Aninat C. et al. Clinical review: the liver in sepsis. Crit. Care. 2012; 16 (5): 235.

52. Stutchfield B.M., Antoine D.J., Mackinnon A.C. et al. CSF1 Restores Innate Immunity Following Liver Injury in Mice and Serum Levels Indicate Outcomes of Patients with Acute Liver Failure. Gastroenterology. 2015; 149 (7): 1896-1909.

53. Zhang S., Yang N., Ni S. et al. Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signa­ling pathway. Int. I. Clin. Exp. Pathol. 2014; 7 (10): 6626-34.

54. Kono T, Kotani H., Asama T. et al. Protective effect of pretreatment with low-dose lipopolysaccharide on D-galactosamine-induced acute liver failure. Int. I. Colorectal. Dis. 2002; 17 (2): 98-103.

55. Sun S., Guo Y., Zhao G. et al. Complement and the alternative pathway play an important role in LPS/D- GalN-induced fulminant hepatic failure. PLoS One. 2011; 6(11).

56. Tapper E.B., Sengupta N., Bonder A. The Incidence and Outcomes of Ischemic Hepatitis: A Systematic Review with Meta-Analysis. Am. I. Med. 2015; 128 (12): 1314-21.

57. Taylor R.M., Tujios S., Jinjuvadia K. et al. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis. Dig. Dis. Sci. 2012; 57 (3): 777-85.

58. Henrion J. Hypoxic hepatitis. Liver Int. 2012; 32 (7): 1039-52.

59. Zhang J., Qian H.G., Leng J.H. et al. Ischemic liver injury after complete occlusion of hepatic artery in the treatment of delayed postoperative arterial bleeding. I. Gastrointest. Surg. 2015; 2.

60. Puviani L., Cavallari G., Bonaiuto E. et al. Portal blood arterialization with an extracorporeal device to treat toxic acute hepatic failure in a swine model. Int. I. Artif. Organs. 2014; 37 (11): 847-53.

61. Zullo A., Cannistra M., Cavallari G. et al. Liver Regeneration Induced By Extracorporeal Portal Vein Arterialization in a Swine Model of Carbon Tetrachloride Intoxication. Transplant Proc. 2015; 47 (7): 2173-5.

62. Datta G., Fuller B.J., Davidson B.R. Molecular mech­anisms of liver ischemia reperfusion injury: insights from transgenic knockout models. World I. Gastroenterol. 2013; 19 (11): 1683-98.

63. Zhang J., Hu W, Xing W et al. The protective role of CD59 and pathogenic role of complement in hepatic ischemia and reperfusion injury. Am. I. Pathol. 2011; 179 (6): 2876-84.

64. Saidi R.F., Rajeshkumar B., Shariftabrizi A. et al. Human Cl inhibitor attenuates liver ischemia-reperfu­sion injury and promotes liver regeneration. I. Surg. Res. 2014; 187 (2): 660-6.

65. He S., Atkinson C., Qiao F. et al. A complement- dependent balance between hepatic ischemia/reperfu- sion injury and liver regeneration in mice. I. Clin. Invest. 2009; И9 (8): 2304-16.

66. Marshall K.M., He S., Zhong Z. et al. Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. I. Exp. Med. 2014; 211 (9): 1793-805.

Об авторах

Ярустовский Михаил Борисович, доктор мед. наук, профессор, заведующий отделением гравитационной хирургии крови и эндоскопии;
Абрамян Марина Владимировна, канд. мед. наук, вед. науч. сотр.;
Комардина Екатерина Викторовна, мл. науч. сотр.

 Если вы заметили опечатку, выделите текст и нажмите Alt+A